Pharmacogenomics and gemcitabine
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/17/suppl_5/v13/476056/mdj942.pdf
Reference32 articles.
1. Cancer incident and mortality in Europe, 2004;Boyle;Ann Oncol,2005
2. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer;Sandler;J Clin Oncol,2000
3. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitbine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975;Smit;J Clin Oncol,2003
4. Efficacy of gemcitabine plus platinum chemotherapy compared withother platinum containing regimens in advanced non-small-cell lung cancers: a meta-analysis of survival outcomes;Le Chevalier;Lung Cancer,2005
5. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Role of ERCC1-XPF;Ferry;Biochem Pharmacol,2000
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. 6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancreatic cancer;Journal of Hazardous Materials;2024-08
2. Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers;Frontiers in Cell and Developmental Biology;2022-12-05
3. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II–IV non-small cell lung cancer: A meta-analysis;The International Journal of Biological Markers;2022-04-11
4. Overexpression of microRNA‑620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD;Experimental and Therapeutic Medicine;2019-05-23
5. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy;British Journal of Surgery;2017-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3